Inclusion Criteria:

        PROCUREMENT

        Referred patients (or respective donors) will initially be consented for procurement of
        blood for generation of the transduced ATL. Eligibility criteria at this stage include:

          -  Diagnosis of recurrent B-cell lymphoma or leukemia (ALL or CLL), or newly diagnosed
             patients unable to receive or complete standard therapy OR diagnosis of
             relapsed/refractory aggressive B-cell lymphoma with a treatment plan that will include
             high dose therapy and autologous stem cell transplantation.

          -  CD19-positive tumor (result can be pending at this time).

          -  Age <= 75 years. The first 3 patients treated on the study should be adults (>= 18
             years).

          -  Hgb greater than or equal to 7.0 (can be a transfused value)

          -  If pheresis required to collect blood:

          -  Creatinine < 1.5 x upper limit normal

          -  AST <1.5 × upper limit normal

          -  PT and APTT <1.5 × upper limit normal

          -  Informed consent explained to, understood by and signed by patient/guardian (and
             donor, where applicable). Patient/guardian given copy of informed consent.

        TREATMENT

          -  Diagnosis of recurrent B-cell lymphoma leukemia (ALL or CLL), or newly diagnosed
             patients unable to receive or complete standard therapy OR diagnosis of
             relapsed/refractory aggressive B-cell lymphoma with a treatment plan that will include
             high dose therapy and autologous stem cell transplantation.

          -  CD19-positive tumor.

          -  Age <= 75 years. The first 3 patients treated on the study should be adults (>= 18
             years).

          -  Bilirubin less than 3 times the upper limit of normal.

          -  AST less than 5 times the upper limit of normal.

          -  Estimated GFR > 50 mL/min

          -  Pulse oximetry of > 90% on room air

          -  Karnofsky or Lansky score of > 60%.

          -  Recovered from acute toxic effects of prior chemotherapy at least one week before
             entering this study. PD1/PDL1 inhibitors will be allowed if medically indicated.

          -  Available autologous or syngeneic activated peripheral blood T cell products (CD28ζ
             and CD28/CD137ζ) with more than or equal to 15% expression of CD19.CAR determined by
             flow cytometry.

          -  Life expectancy of greater than 12 weeks.

          -  Sexually active patients must be willing to utilize one of the more effective birth
             control methods during the study and for 6 months after the study is concluded. The
             male partner should use a condom.

          -  Patients or legal guardians must sign an informed consent indicating that they are
             aware this is a research study and have been told of its possible benefits and toxic
             side effects. Patients or their guardians will be given a copy of the consent form.

        Exclusion Criteria:

        PROCUREMENT

          -  Active infection requiring antibiotics.

          -  No history of other cancer (except non-melanoma skin cancer or in situ breast cancer
             or cervix cancer) unless the tumor was successfully treated with curative intent at
             least 2 years before trial entry.

        TREATMENT

          -  Currently receiving any investigational agents or received any tumor vaccines within
             the previous 6 weeks. (Note treatment with PD1/PDL1 inhibitors is allowed.)

          -  History of hypersensitivity reactions to murine protein-containing products.

          -  Pregnant or lactating.

          -  Tumor in a location where enlargement could cause airway obstruction.

          -  Active infection with HIV or HTLV.